Pressure BioSciences, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT (USD $)	Series C Preferred Stock	Series D Preferred Stock	Series E Preferred Stock	Series G Preferred Stock	Series H Preferred Stock	Series J Preferred Stock	Series K Preferred Stock	Common Stock	Stock Warrants	Additional Paid-In Capital	Accumulated Deficit	Total
Beginning Balance - Amount at Dec. 31, 2011	$ 881	$ 7						$ 67,240	$ 2,203,101	$ 13,823,875	$ (16,503,440)	$ (408,336)
Beginning Balance - Shares at Dec. 31, 2011	88,098	743						6,723,993
Stock-based compensation										133,193		133,193
Issuance of Series E convertible preferred stock, Shares			500
Issuance of Series E convertible preferred stock, Amount			5							499,995		500,000
Issuance of Series G convertible preferred stock, Shares				120,680
Issuance of Series G convertible preferred stock, Amount				1,207					104,301	497,867		603,375
Fair value of common stock issued for services, Shares								1,125,000
Fair value of common stock issued for services, Amount								11,250		343,297		354,547
Offering costs for issuance of preferred stock										(194,367)		(194,367)
Issuance of warrants in connection short-term loans									45,156			45,156
Issuance of warrants for services, Shares				24,640
Issuance of warrants for services, Amount				246					11,883			11,883
Issuance of Series G preferred stock in lieu of cash for Board of Director fees, Amount									20,596	102,358		123,200
Warrant modifications									323,556		(190,891)	132,665
Conversion of preferred stock to common stock, Shares	(88,098)	(443)	(500)					2,723,540
Conversion of preferred stock to common stock, Amount	(881)	(4)	(5)					27,235		(24,549)
Common stock paid-in-kind dividends earned											(278,184)	(278,184)
Series E dividend paid in cash											(196,819)	(196,819)
Issuance of common stock in private placement, Shares								971,867
Issuance of common stock in private placement, Amount								9,719	307,403	482,878		800,000
Issuance of common stock for dividends paid-in-kind, Shares								604,867
Issuance of common stock for dividends paid-in-kind, Amount								6,049		276,271		284,116
Net loss											(3,450,205)	(3,450,205)
Ending Balance, Amount at Dec. 31, 2012		3		1,453				121,493	3,015,996	15,940,818	(20,619,539)	(1,539,776)
Ending Balance, Shares at Dec. 31, 2012		300		145,320				12,149,267
Stock-based compensation												136,796
Fair value of common stock issued for services, Shares								875,000
Fair value of common stock issued for services, Amount								8,750		467,962		476,712
Offering costs for issuance of preferred stock										(67,739)		(67,739)
Issuance of warrants in connection short-term loans									73,647			73,676
Issuance of warrants for services, Amount									21,028			21,028
Beneficial conversion of issued preferred stock										1,002,602	(1,002,602)
Common stock paid-in-kind dividends earned											(160,420)	(160,420)
Issuance of Series H convertible preferred stock, Shares								(1,000,000)
Issuance of Series H convertible preferred stock, Amount								(10,000)		9,900
Issuance of Series J convertible preferred stock, Shares						5,088
Issuance of Series J convertible preferred stock, Amount						51			885,309	1,149,340		2,034,700
Issuance of Series K convertible preferred stock, Shares							4,000
Issuance of Series K convertible preferred stock, Amount							40		271,422	728,538		1,000,000
Reclassification of conversion option liabilities										141,704		141,704
Net loss											(4,084,427)	(4,084,427)
Ending Balance, Amount at Dec. 31, 2013		$ 3		$ 1,453	$ 100	$ 51	$ 40	$ 120,243	$ 4,267,402	$ 19,509,921	$ (25,866,988)	$ (1,967,775)
Ending Balance, Shares at Dec. 31, 2013		300		145,320	10,000	5,088	4,000	12,024,267